Drug Database
SU

sumatriptan succinate (Zelrix / NP101 / Zecuity)

✓ Approved

Nupathe Inc. · HTR1D · Small Molecule

What is sumatriptan succinate?

sumatriptan succinate is a small molecule developed by Nupathe Inc.. It is approved for therapeutic indications via topical or transdermal.

Drug Profile

Brand NamesZelrix, NP101, Zecuity
CompanyNupathe Inc.
Drug ClassSmall Molecule
Molecular TargetHTR1D
RouteTopical, Transdermal
StatusApproved

Mechanism of Action

Molecular Targets

sumatriptan succinate acts on 1 molecular target:

HTR1D5-hydroxytryptamine receptor 1D (HTR1DA, HT1DA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

sumatriptan succinate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersMigraine✓ Approved

Related Research Articles

PubMedJournal of biological engineering2026-11-11

Bionanofluids enhance methane bioconversion and reshape time-resolved methanotroph physiology.

Kang Eungsu E, Hong Hyo Jin HJ, Noh Hyeon Bang HB, Hyung Ji Sung JS et al.

Methane (CH4) is an attractive carbon feedstock for sustainable biomanufacturing, but poor CH4 solubility and gas-liquid mass-transfer limitations continue to constrain methanotroph-based CH4 valorization. Here, we evaluated biocompatible bionanofluids as additive-based process intensification tools and examined whether two operationally distinct bionanofluid application strategies produce distinct time-dependent physiological responses beyond simple growth enhancement. Two bionanofluids, chitosan/oleamide (CS/OA) nanoparticles and tannic acid-Fe3+ complex-coated cellulose nanocrystals (TA-Fe3+CNCs), were evaluated in 5-L cultures of Methylosinus trichosporium OB3b using two different application approaches: CS/OA seed adaptation followed by cultivation in conventional medium, and TA-Fe3+CNCs supplementation in the main culture. In both approaches, time-resolved profiling of gas uptake, nitrogen species, extracellular metabolites, and poly(3-hydroxybutyrate) (PHB) showed higher CH4 and O2 utilization, with 1.5-1.6- and 2.0-2.1-fold increases in specific CH4 and O2 uptake rates, respectively, and faster growth, with 1.3-1.5-fold higher µmax, than in the conventional control. These changes were accompanied by consistently lower PHB content, faster nitrate depletion, higher ammonium accumulation, and distinct extracellular metabolite patterns. Notably, CS/OA seed adaptation was associated with transient succinate accumulation during exponential growth, whereas TA-Fe3+CNCs supplementation led to faster methanol accumulation without succinate release. These observations are consistent with a process-level response in which higher CH4/O2 uptake and faster growth coincided with lower PHB content under the tested conditions. As an initial proof-of-concept experiment, a consecutive strategy combining CS/OA seed adaptation with TA-Fe3+CNCs supplementation in Methylomonas sp. DH-1 was associated with greater transient succinate accumulation and a higher peak succinate titer than under the conventional condition. Comparative time-resolved profiling of two different bionanofluid approaches indicated that bionanofluid application was associated with higher CH4/O2 uptake, faster growth, lower PHB accumulation, and distinct time-dependent metabolite patterns under the tested conditions. These findings support the use of biocompatible bionanofluids as practical media additives that can be applied without major bioreactor redesign and can motivate future component-controlled testing of sequential strategies for growth-linked CH4 bioconversion.

PubMedMolecular medicine (Cambridge, Mass.)2026-11-10

Succinate promotes renal inflammation and fibrosis by activating the NLRP3 inflammasome in macrophages via GPR91 signaling.

Zhang Yan Y, Cheng Jiawei J, Liao Xiaohua X, He Xin X et al.

Aberrant succinate accumulation functions as a potent metabolic danger signal in various inflammatory diseases. However, the specific contribution of the succinate-GPR91 signaling axis to the pathogenesis of renal fibrosis remains incompletely defined. Succinate levels were analyzed in kidney tissues from patients with obstructive nephropathy and mice with unilateral ureteral obstruction (UUO). The impact of succinate on renal fibrosis was evaluated using exogenous succinate administration and pharmacological inhibition with dimethyl malonate (DMM). Mechanistic studies employed Gpr91-knockout mice, NLRP3-knockout mice, and cultured macrophages to dissect the downstream signaling pathways linking metabolic alterations to innate immunity. We observed significantly elevated succinate levels in fibrotic kidneys from both patients and UUO mice, which correlated positively with disease severity. Functionally, exogenous succinate markedly exacerbated renal inflammation and fibrosis, whereas pharmacological inhibition with DMM attenuated these pathological changes. Mechanistically, we demonstrated that succinate mainly activates its receptor GPR91 on macrophages to trigger NLRP3 inflammasome assembly and IL-1β secretion, a pro-fibrotic cascade effectively abolished by genetic ablation of Gpr91 or NLRP3 in vivo, or by their pharmacological blockade in vitro. This study establishes the succinate-GPR91 axis as a pivotal metabolic driver of renal fibrosis, likely primarily through macrophage-mediated NLRP3 inflammasome activation. Targeting this pathway represents a promising therapeutic strategy for interfering with the progression of chronic kidney disease.

PubMedFrontiers in endocrinology2026-11-10

Urinary succinate is associated with kidney injury in type 2 diabetes mellitus: a cross-sectional analysis.

Cai Ting T, Jiao Yihan Y, Chen Xinyu X, Kong Xinyue X et al.

Diabetic kidney disease (DKD) is a common microvascular complication in patients with type 2 diabetes mellitus (T2DM), yet reliable biomarkers for disease assessment and effective risk stratification remain limited. Succinate is a signaling molecule implicated in kidney diseases. This study aimed to investigate the association between urinary succinate and kidney injury in patients with T2DM. Cross-sectional study of 240 participants: healthy controls (n = 25), patients with non-DKD (n =40), and 175 patients with T2DM (85 without DKD and 90 with DKD). Urinary succinate levels were measured using a colorimetric assay kit. Urinary succinate levels were significantly elevated in patients with T2DM but not in patients with non-DKD, with the highest levels observed in patients with DKD. Urinary succinate correlated negatively with estimated glomerular filtration rate (eGFR) and positively with serum creatinine, urinary albumin-to-creatinine ratio (UACR), urinary N-acetyl-β-D-glucosaminidase (NAG), and urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with DKD, but only correlated with urinary NAG in patients with T2DM without DKD. In multivariable liner regression analysis, urinary succinate was found to be independently associated with eGFR in patients with DKD after adjustment for age, male sex, smoking history, hypertension, HbA1c > 7.0%, uric acid, UACR, and the use of renin-angiotensin system inhibitors (RASi) and sodium-glucose co-transporter 2 inhibitors (SGLT2i). Receiver operating characteristic (ROC) analysis for detecting eGFR < 60 mL/min/1.73m2 in DKD yielded an AUC of 0.70, with a sensitivity of 57.14% and a specificity of 75.00%. Urinary succinate levels are elevated in patients with T2DM, particularly in DKD, but not increased in patients with non-DKD. Urinary succinate is independently associated with eGFR, and shows moderate diagnostic performance for renal insufficiency in DKD. These findings suggest that urinary succinate may serve as a potential non-invasive biomarker for diabetes-related kidney injury. Prospective studies are needed to evaluate its predictive value for early detection and disease progression of DKD.

PubMedFrontiers in microbiology2026-11-10

Fusobacterium nucleatum-associated metabolites in disease pathogenesis: from cancer to immunotherapy.

Farah Husni H, PadmaPriya G G, Sahoo Samir S, Alhasso Bahjat B et al.

Fusobacterium, especially Fusobacterium nucleatum, has emerged as a metabolically active pathobiont that can affect host physiology and disease pathogenesis. Through its ability to produce and regulate various metabolites, Fusobacterium can shape immune response, cellular metabolism, and disease progression. Short-chain fatty acids (SCFAs), being part of Fusobacterium-associated metabolic changes observed during disease, are involved in microbial cross-feeding and can affect neutrophil recruitment and inflammatory signaling through free fatty acid receptors. In the case of colorectal cancer (CRC), Fusobacterium-derived metabolites can impact tumor and immune cell phenotype via a number of mechanisms, including aryl hydrocarbon receptor (AhR) activation via indole derivatives, inflammatory and metabolic signaling via hydrogen sulfide, as well as an increase in Glucose transporter 1 (GLUT1) expression, lactate production, and histone lactylation via formate-related metabolites. Besides, F. nucleatum can reshape tumor-cell metabolism, including cholesterol biosynthesis through miR-130a-3p-mediated inhibition of AMP-activated protein kinase (AMPK) signaling, whereas butyrate has been reported to counteract this metabolic phenotype in experimental CRC models. In addition, F. nucleatum-associated succinate has been shown to suppress cGAS-Interferon beta (IFN-β) signaling, thereby reducing antitumor immune activation, impairing CD8+ T-cell trafficking, and promoting immune escape and resistance to anti-Programmed Cell Death Protein 1 (PD-1) therapy. The present review provides an overview of current understanding of the biological roles of Fusobacterium-derived metabolites, focusing on SCFAs, succinate, indole derivatives, hydrogen sulfide, and formate-related metabolites.

PubMedFrontiers in microbiology2026-11-10

Gut microbiota-host co-metabolism in sepsis and critical illness: source, compartment, immune state, and host defense.

Wu Chongchong C, Liu Rui R

Critical illness can profoundly disturb the intestinal microbiota-metabolite-host immune axis through the combined effects of shock, hypoxia, altered nutritional intake, antimicrobial exposure, organ dysfunction, and impaired epithelial barrier integrity. These changes can reshape microbial metabolic capacity, host co-metabolism, and systemic metabolite exposure, while the host may simultaneously exhibit overlapping features of hyperinflammation, immune tolerance, lymphocyte dysfunction, impaired antimicrobial defense, and tissue repair. Metabolites generated through microbial metabolism or shared microbial-host pathways may therefore contribute to immune reprogramming, although their effects are highly context dependent and cannot be regarded as uniformly beneficial or detrimental. This narrative review examines short-chain fatty acids, tryptophan-derived indoles, secondary bile acids, succinate, lactate, trimethylamine N-oxide, polyamines, and aromatic metabolites, with particular attention to source attribution, anatomical compartment, host co-metabolism, receptor signaling, and their potential influence on antimicrobial immunity. These metabolites may act through G-protein-coupled receptors, AhR, PXR, FXR, TGR5, VDR, HIF-1α, inflammasome pathways, mitochondrial signaling, and epigenetic mechanisms to modulate macrophages, neutrophils, dendritic cells, innate lymphoid cells, T lymphocytes, epithelial barriers, and endothelial responses. The direction and magnitude of these effects are likely to vary according to timing, concentration, anatomical compartment, immune-cell state, pathogen burden, and renal or hepatic clearance. Within this framework, attenuation of inflammatory signaling may help limit early collateral tissue injury, yet the same response could become disadvantageous when antimicrobial competence is already impaired. Similarly, succinate and lactate may reflect or contribute to distinct inflammatory, regulatory, or reparative programs depending on whether they arise from microbial or host metabolism and whether they act within intracellular or extracellular compartments. Human studies in critically ill populations have linked dysbiosis and metabolomic alterations with secondary infection, prolonged organ support, and mortality; however, most have not been able to resolve microbial source attribution or establish causal mediation. Future work would therefore benefit from integrating longitudinal microbiome, metabolome, immune-function, and organ-clearance measurements with source-resolved approaches, including isotope tracing, as well as state-specific and trajectory-informed clinical endpoints. Microbiome-directed interventions may be most appropriately investigated as context-dependent modulators of host defense rather than as broadly anti-inflammatory strategies.

PubMedOpen biology2026-11-10

Metabolic dysfunction in Friedreich ataxia.

Lynch David D, Mesaros Clementina C, Mercado Ayon Elizabeth E, Dong Yi Na YN

Friedreich ataxia (FRDA) is a metabolic disease with two faces. Loss of iron-sulfur cluster biogenesis disables oxidative phosphorylation, the Krebs cycle and the oxidation of fatty acids and ketone bodies, forcing tissues onto glycolysis and stranding lipid in droplets and as ceramide. The second aspect is on the supply side. A frataxin-deficient liver and adipose tissue deliver inadequate lipoprotein, fatty acid and ketone cargo to the heart, skeletal muscle and nervous system, the organs that depend most on imported fuel. Together, these lesions produce a cardiomyopathy that behaves like an engine out of fuel, a mixed diabetes of insulin deficiency and insulin resistance, low lean and bone mass and a redox-collapsed, ferroptosis-prone state. This review traces that logic from the cell to the organ to the whole body. The same map defines a compact panel of blood-based biomarkers, anchored on frataxin protein itself and extended by chain-resolved ceramides and by the succinate : fumarate, BHB : acetoacetate, NAD+ : NADH and GSH : GSSG ratios. It also nominates targets that do not require restoration of frataxin, including NRF2 activation, ferroptosis inhibition, NAD+ and sirtuin repletion, PPARgamma agonism, anaplerosis and ketone-based therapy. Reframing FRDA as a disorder of fuel logistics, rather than of fuel combustion alone, explains why a globally reduced protein produces a selective yet multisystem disease.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about sumatriptan succinate